Hamlet BioPharma Investor Relations Material
Latest events
Investor Update
Hamlet BioPharma
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Hamlet BioPharma
Access all reports
Hamlet Pharma AB, a pharmaceutical company, engages in the research and development of cancer drugs. The company's lead product candidate is a patented drug that combines the active ingredient Bisantrene-Guanidinylpenicillamine in a galenic form suitable for oral administration. Its BAR treatment is administered through small pills that slowly release the active ingredient into the upper part of the gastrointestinal tract. The company is headquartered in Malmö, Sweden.
Latest articles
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
HAMLET
Country
🇸🇪 Sweden